Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Consolidated Net Income (2016 - 2025)

Rhythm Pharmaceuticals has reported Consolidated Net Income over the past 10 years, most recently at -$47.5 million for Q4 2025.

  • Quarterly Consolidated Net Income fell 9.71% to -$47.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$196.6 million through Dec 2025, up 24.57% year-over-year, with the annual reading at -$196.5 million for FY2025, 24.58% up from the prior year.
  • Consolidated Net Income was -$47.5 million for Q4 2025 at Rhythm Pharmaceuticals, up from -$52.9 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $43.8 million in Q1 2021 and troughed at -$141.4 million in Q1 2024.
  • The 5-year median for Consolidated Net Income is -$44.5 million (2022), against an average of -$45.0 million.
  • Year-over-year, Consolidated Net Income soared 228.06% in 2021 and then tumbled 220.07% in 2022.
  • A 5-year view of Consolidated Net Income shows it stood at -$50.9 million in 2021, then grew by 16.44% to -$42.5 million in 2022, then increased by 2.02% to -$41.6 million in 2023, then fell by 4.07% to -$43.3 million in 2024, then dropped by 9.71% to -$47.5 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Consolidated Net Income are -$47.5 million (Q4 2025), -$52.9 million (Q3 2025), and -$46.6 million (Q2 2025).